Epstein-Barr Virus Infections Clinical Trials

33 clinical trials for Epstein-Barr Virus Infections across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas — RECRUITING · PHASE2
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Anti-viral T-cell Therapy by Gamma Capture — RECRUITING · PHASE1
• R-MVST Cells for Treatment of Viral Infections — RECRUITING · PHASE1
• Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity — RECRUITING · PHASE1
• EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection — RECRUITING · PHASE2
• Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft — RECRUITING · PHASE4
• Evaluation of CMV/EBV-CMI in Haploid HSCT — RECRUITING
• Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS Patients — COMPLETED
• A Study of the Safety and Efficacy of EBV Specific T-cell Lines — COMPLETED · PHASE1
• Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) — TERMINATED · PHASE1
• Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant — TERMINATED · PHASE2
• Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant — COMPLETED · PHASE2
• Study on Infectious Mononucleosis in Munich — COMPLETED
• Early Detection of Epstein-Barr Virus Related Disease. — COMPLETED
• Immunodeficiency for Severe Epstein-Barr Virus Infection — COMPLETED
• Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial — OTHER · PHASE1
• ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation — COMPLETED · PHASE2
• Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV — COMPLETED · PHASE1
• Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy — COMPLETED · PHASE2
• Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) — COMPLETED · PHASE1
• Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). — COMPLETED · PHASE1
• A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma — COMPLETED · PHASE1
• Bortezomib Plus Rituximab for EBV+ PTLD — COMPLETED · PHASE2
• Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations — COMPLETED
• Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents — COMPLETED
• A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin — COMPLETED
• EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients — COMPLETED
• Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts — COMPLETED · PHASE1
• Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) — COMPLETED · PHASE1
• Modified Vaccinia Ankara (MVA) Vaccine Study — COMPLETED · PHASE1
• Surveillance Study of Viral Infections Following Lung Transplantation — COMPLETED
• The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis — OTHER

Refine this search